366 related articles for article (PubMed ID: 25992210)
1. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.
Grafone T; Palmisano M; Nicci C; Storti S
Oncol Rev; 2012 Mar; 6(1):e8. PubMed ID: 25992210
[TBL] [Abstract][Full Text] [Related]
2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
3. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
4. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
[TBL] [Abstract][Full Text] [Related]
5. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
6. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
[TBL] [Abstract][Full Text] [Related]
8. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
10. [FLT3 Mutations in Acute Myeloid Leukemia].
Shoji T; Kida Y; Yamashita K; Ichiyama S
Rinsho Byori; 2017 Jan; 65(1):44-51. PubMed ID: 30695511
[TBL] [Abstract][Full Text] [Related]
11. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
Kiyoi H; Naoe T
Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction of oncogenic Flt3.
Choudhary C; Müller-Tidow C; Berdel WE; Serve H
Int J Hematol; 2005 Aug; 82(2):93-9. PubMed ID: 16146838
[TBL] [Abstract][Full Text] [Related]
13. Mutant FLT3 signaling contributes to a block in myeloid differentiation.
Zheng R; Small D
Leuk Lymphoma; 2005 Dec; 46(12):1679-87. PubMed ID: 16263569
[TBL] [Abstract][Full Text] [Related]
14. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
Masson K; Rönnstrand L
Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
[TBL] [Abstract][Full Text] [Related]
16. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
Scheijen B; Ngo HT; Kang H; Griffin JD
Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
18. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors: clinical potential in acute myeloid leukemia.
Hospital MA; Green AS; Maciel TT; Moura IC; Leung AY; Bouscary D; Tamburini J
Onco Targets Ther; 2017; 10():607-615. PubMed ID: 28223820
[TBL] [Abstract][Full Text] [Related]
20. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
